Theramex timetable extended for UK review of deal concessions
MLex Summary: Theramex’s offer to divest the UK rights to two menopause treatments, to get antitrust approval to acquire the European rights, will be considered by the Competition and Markets Authority...To view the full article, register now.
Already a subscriber? Click here to view full article